Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 1
1955 1
1956 2
1957 5
1958 5
1959 1
1960 1
1961 3
1962 3
1963 2
1964 2
1967 1
1968 1
1969 1
1971 2
1972 1
1973 3
1974 2
1975 4
1976 3
1977 6
1978 1
1979 6
1980 4
1981 2
1983 4
1984 2
1985 2
1986 2
1987 4
1989 3
1990 3
1991 3
1992 3
1993 6
1994 27
1995 25
1996 23
1997 33
1998 37
1999 44
2000 40
2001 46
2002 45
2003 28
2004 36
2005 20
2006 32
2007 37
2008 36
2009 26
2010 37
2011 58
2012 49
2013 79
2014 119
2015 118
2016 124
2017 137
2018 128
2019 162
2020 191
2021 218
2022 167
2023 129
2024 45

Text availability

Article attribute

Article type

Publication date

Search Results

849 results

Results by year

Filters applied: . Clear all
Page 1
Agammaglobulinemia: from X-linked to Autosomal Forms of Disease.
Cardenas-Morales M, Hernandez-Trujillo VP. Cardenas-Morales M, et al. Clin Rev Allergy Immunol. 2022 Aug;63(1):22-35. doi: 10.1007/s12016-021-08870-5. Epub 2021 Jul 9. Clin Rev Allergy Immunol. 2022. PMID: 34241796 Free PMC article. Review.
Interruptions or alterations in the B cell development pathway can lead to primary B cell immunodeficiency with resultant absence or diminished immunoglobulin production. While the most common cause of congenital agammaglobulinemia is X-linked agammaglobulinemia (XL …
Interruptions or alterations in the B cell development pathway can lead to primary B cell immunodeficiency with resultant absence or diminis …
Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE, Brown JR. Ahn IE, et al. Front Immunol. 2021 Jun 23;12:687458. doi: 10.3389/fimmu.2021.687458. eCollection 2021. Front Immunol. 2021. PMID: 34248972 Free PMC article. Review.
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L. Sibaud V, et al. Am J Clin Dermatol. 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x. Am J Clin Dermatol. 2020. PMID: 32613545 Review.
The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocytic leukemia and other B cell malignancies. ...
The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymph …
Managing toxicities of Bruton tyrosine kinase inhibitors.
Lipsky A, Lamanna N. Lipsky A, et al. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):336-345. doi: 10.1182/hematology.2020000118. Hematology Am Soc Hematol Educ Program. 2020. PMID: 33275698 Free PMC article. Review.
Inhibition of Bruton's tyrosine kinase (BTK) has revolutionized the treatment landscape for patients with chronic lymphocytic leukemia (CLL). ...
Inhibition of Bruton's tyrosine kinase (BTK) has revolutionized the treatment landscape for patients with chronic lymphocytic …
X-linked Agammaglobulinemia.
Suri D, Rawat A, Singh S. Suri D, et al. Indian J Pediatr. 2016 Apr;83(4):331-7. doi: 10.1007/s12098-015-2024-8. Epub 2016 Feb 24. Indian J Pediatr. 2016. PMID: 26909497 Review.
X-linked agammaglobulinemia (XLA) is one of the commonest primary immune deficiencies encountered in pediatric clinical practice. ...
X-linked agammaglobulinemia (XLA) is one of the commonest primary immune deficiencies encountered in pediatric clinical practice. ...
X-Linked Agammaglobulinemia.
Smith CIE, Berglöf A. Smith CIE, et al. 2001 Apr 5 [updated 2016 Aug 4]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2001 Apr 5 [updated 2016 Aug 4]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301626 Free Books & Documents. Review.
CLINICAL CHARACTERISTICS: X-linked agammaglobulinemia (XLA) is characterized by recurrent bacterial infections in affected males in the first two years of life. ...
CLINICAL CHARACTERISTICS: X-linked agammaglobulinemia (XLA) is characterized by recurrent bacterial infections in affected males in t …
Waldenström macroglobulinemia.
Baďurová K, Gregorová J, Vlachová M, Krejčí M, Ševčíková S. Baďurová K, et al. Klin Onkol. 2021 Fall;34(6):428-433. doi: 10.48095/ccko2021428. Klin Onkol. 2021. PMID: 34911327 Review. English.
The detection of MYD88 mutation is important for a correct therapeutic strategy, since a Brutons tyrosine kinase inhibitor, ibrutinib, is most effective in patients with mutated MYD88 and wt CXCR4. ...
The detection of MYD88 mutation is important for a correct therapeutic strategy, since a Brutons tyrosine kinase inhibitor, ibrutinib …
Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S, Dammeijer F, Hendriks RW. Pal Singh S, et al. Mol Cancer. 2018 Feb 19;17(1):57. doi: 10.1186/s12943-018-0779-z. Mol Cancer. 2018. PMID: 29455639 Free PMC article. Review.
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary immunodefic …
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for …
The role of Bruton's tyrosine kinase in the immune system and disease.
McDonald C, Xanthopoulos C, Kostareli E. McDonald C, et al. Immunology. 2021 Dec;164(4):722-736. doi: 10.1111/imm.13416. Epub 2021 Oct 4. Immunology. 2021. PMID: 34534359 Free PMC article. Review.
Bruton's tyrosine kinase (BTK) is a TEC kinase with a multifaceted role in B-cell biology and function, highlighted by its position as a critical component of the B-cell receptor signalling pathway. ...
Bruton's tyrosine kinase (BTK) is a TEC kinase with a multifaceted role in B-cell biology and function, highlighted by its pos …
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS, Ou YC, Trotman J, Opat S. Tam CS, et al. Expert Rev Clin Pharmacol. 2021 Nov;14(11):1329-1344. doi: 10.1080/17512433.2021.1978288. Epub 2021 Sep 20. Expert Rev Clin Pharmacol. 2021. PMID: 34491123 Review.
Introduction: Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell lymphomas. ...
Introduction: Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell lymphomas. ...
849 results